Specifically, histone lactylation at H3K18 and lactylation of fatty acid synthase (FASN) has been reported to facilitate hepatic lipid accumulation, suggesting that targeting lactylation pathways may represent a promising therapeutic strategy for MASLD management [76,77]. This evidence concerns the gene FASN and metabolic dysfunction-associated steatotic liver disease.